These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11121134)

  • 1. Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo.
    Aragane Y; Maeda A; Cui CY; Tezuka T; Kaneda Y; Schwarz T
    J Invest Dermatol; 2000 Dec; 115(6):1008-14. PubMed ID: 11121134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
    Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
    Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit.
    Bernassola F; Scheuerpflug C; Herr I; Krammer PH; Debatin KM; Melino G
    Cell Death Differ; 1999 Jul; 6(7):652-60. PubMed ID: 10453076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
    Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
    J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L.
    Aragane Y; Kulms D; Metze D; Wilkes G; Pöppelmann B; Luger TA; Schwarz T
    J Cell Biol; 1998 Jan; 140(1):171-82. PubMed ID: 9425165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
    Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
    Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of murine hepatocyte death by membrane-bound CD95 (Fas/APO-1)-ligand: characterization of an in vitro system.
    Schlosser SF; Azzaroli F; Dao T; Hingorani R; Crispe IN; Boyer JL
    Hepatology; 2000 Oct; 32(4 Pt 1):779-85. PubMed ID: 11003622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression.
    Fecker LF; Geilen CC; Hossini AM; Schwarz C; Fechner H; Bartlett DL; Orfanos CE; Eberle J
    J Invest Dermatol; 2005 Jan; 124(1):221-8. PubMed ID: 15654977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
    Chatterjee D; Schmitz I; Krueger A; Yeung K; Kirchhoff S; Krammer PH; Peter ME; Wyche JH; Pantazis P
    Cancer Res; 2001 Oct; 61(19):7148-54. PubMed ID: 11585748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence resonance energy transfer analysis of proapoptotic CD95-EGF receptor interactions in Huh7 cells.
    Eberle A; Reinehr R; Becker S; Häussinger D
    Hepatology; 2005 Feb; 41(2):315-26. PubMed ID: 15660394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand.
    Müller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH
    Eur J Immunol; 1995 Oct; 25(10):2996-9. PubMed ID: 7589104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.
    Cerrato JA; Khan T; Koul D; Lang FF; Conrad CA; Yung WK; Liu TJ
    Int J Oncol; 2004 Feb; 24(2):409-17. PubMed ID: 14719118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
    Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
    Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma.
    Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U
    Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis.
    Roth W; Wagenknecht B; Klumpp A; Naumann U; Hahne M; Tschopp J; Weller M
    Cell Death Differ; 2001 Apr; 8(4):403-10. PubMed ID: 11550092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system.
    Eichhorst ST; Müerköster S; Weigand MA; Krammer PH
    Cancer Res; 2001 Jan; 61(1):243-8. PubMed ID: 11196169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paneth cells express high levels of CD95 ligand transcripts: a unique property among gastrointestinal epithelia.
    Möller P; Walczak H; Reidl S; Sträter J; Krammer PH
    Am J Pathol; 1996 Jul; 149(1):9-13. PubMed ID: 8686766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
    J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
    Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
    Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.
    Li-Weber M; Laur O; Dern K; Krammer PH
    Eur J Immunol; 2000 Feb; 30(2):661-70. PubMed ID: 10671224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.